Safety, Tolerability, Pharmacokinetics, & Therapeutic Efficacy of

Status Completed

Clinical Trial Summary

Primary Objective: To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by the change of the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) Secondary Objectives: - To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS - To evaluate the therapeutic efficacy on fatigue of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS - To evaluate the pharmacokinetic (PK) exposure of one dose level of SAR441344 over 12 weeks in adult patients with pSjS - To evaluate the safety and tolerability of one dose level of SAR441344 versus placebo in adult patients with pSjS as determined by adverse events (AEs) - To evaluate the local tolerability of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS - To evaluate the safety and tolerability of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS determined by electrocardiogram, vital signs, and laboratory evaluations - To measure the immunogenicity of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with pSjS This is a multicenter, randomized, double blind, placebo controlled, parallel group proof of concept Phase 2 study to evaluate the therapeutic efficacy of SAR441344 in adult patients with primary Sjögren's syndrome (pSjS), as well as safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD). - Study visit frequency: every 2 weeks in the treatment period and every 4 weeks in the follow-up period. - The total duration of the study will be 24 weeks (28 weeks including maximum screening duration) for each participant, including a 12-week treatment period and a 12-week follow-up period.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04572841
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 2
Start date	November 12, 2020
Completion date	February 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03248518` - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases	N/A
Completed	`NCT04968912` - A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)	Phase 2
Completed	`NCT03203382` - Corneal Nerve Structure in Sjogren's
Completed	`NCT00809003` - Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease	N/A
Completed	`NCT00023491` - Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells	N/A
Completed	`NCT05005806` - Fish Oil (Omega 3 ) in Sjogren's Syndrome	Phase 2/Phase 3
Enrolling by invitation	`NCT03436576` - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye	Phase 3
Terminated	`NCT04143841` - Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease	N/A
Completed	`NCT03611283` - Topical Management of Xerostomia With Dry Mouth Products	N/A
Recruiting	`NCT06104124` - A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity	Phase 3
Recruiting	`NCT05115487` - Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
Recruiting	`NCT05383677` - Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome	Phase 2
Not yet recruiting	`NCT03938207` - Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
Completed	`NCT04239521` - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed	`NCT04546542` - Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
Recruiting	`NCT05085431` - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome	Early Phase 1
Completed	`NCT00565526` - Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome
Completed	`NCT01369589` - An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness	Phase 1/Phase 2
Completed	`NCT00001953` - The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers	N/A
Completed	`NCT00001731` - Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) — phaethuSA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms